For example, sarcoma, mesothelioma, pancreatic cancer and microsatellite-stable colorectal cancers have low response rates to antibodies targeting PD1, PD-L1 or CTLA-4 (3–5). This evidence concerns the gene CTLA4 and mesothelioma.